Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.

You may also be interested in...



Lilly Zyprexa, Symbyax Labeling Strengthened

Update elevates information on weight gain and hyperlipidemia from adverse event precaution to “Warning” status and adds to elevated blood sugar warning.

Lilly Zyprexa, Symbyax Labeling Strengthened

Update elevates information on weight gain and hyperlipidemia from adverse event precaution to “Warning” status and adds to elevated blood sugar warning.

Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug

Catie research published in the American Journal of Psychiatry shows that treatment with older drugs may be less expensive but just as effective.

Related Content

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel